Literature DB >> 15145338

A case of childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn.

Marian A Kroos1, Janbernd Kirschner, Frank N Gellerich, Monique M P Hermans, Ans T Van Der Ploeg, Arnold J J Reuser, Rudolf Korinthenberg.   

Abstract

A six-year-old child presented at 8 months of age with proximal muscle weakness and mild cardiac hypertrophy. Some alpha-glucosidase activity was detected in muscle but not in fibroblasts. As none of the two pathogenic mutations, [c.1933G>A]+[c.2702T>A] (Asp645Asn/Leu901Gln), led to detectable alpha-glucosidase activity upon expression in COS cells, the phenotype of the patient remained unexplained. A functionally comparable set of mutations, Asp645Asn/insGnt2243, was reported previously to cause classic infantile Pompe disease [Biochem Biophys Res Commun 244 (1998) 921]. We conclude that secondary genetic or environmental factors can be decisive for the phenotypic outcome of classic infantile versus childhood Pompe disease, when the acid alpha-glucosidase activity is extremely low. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145338     DOI: 10.1016/j.nmd.2004.02.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  4 in total

1.  Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.

Authors:  Monica Del Rizzo; Marina Fanin; Alessia Cerutti; Chiara Cazzorla; Ornella Milanesi; Anna Chiara Nascimbeni; Corrado Angelini; Laura Giordano; Andrea Bordugo; Alberto B Burlina
Journal:  J Inherit Metab Dis       Date:  2010-09-10       Impact factor: 4.982

2.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

3.  The emerging phenotype of long-term survivors with infantile Pompe disease.

Authors:  Sean N Prater; Suhrad G Banugaria; Stephanie M DeArmey; Eleanor G Botha; Erin M Stege; Laura E Case; Harrison N Jones; Chanika Phornphutkul; Raymond Y Wang; Sarah P Young; Priya S Kishnani
Journal:  Genet Med       Date:  2012-04-26       Impact factor: 8.822

4.  Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants.

Authors:  Lei Yang; Xiaohui Zhang; Liren Wang; Shuming Yin; Biyun Zhu; Ling Xie; Qiuhui Duan; Huiqiong Hu; Rui Zheng; Yu Wei; Liangyue Peng; Honghui Han; Jiqin Zhang; Wenjuan Qiu; Hongquan Geng; Stefan Siwko; Xueli Zhang; Mingyao Liu; Dali Li
Journal:  Protein Cell       Date:  2018-09       Impact factor: 14.870

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.